Fig. 3 | Leukemia

Fig. 3

From: Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Fig. 3

Progression-free survival by a del(11q) status and b IGHV mutational status. Survival analyses are from randomization until event or censored at last follow-up; vertical tick marks indicate censored patients. CI confidence interval, del(11q) chromosome 11q deletion, IGHV immunoglobulin heavy chain variable region, NE not estimable, NR not reached, PFS progression-free survival

Back to article page